8-K: TuHURA Biosciences Secures $15.6M in Direct Offering

TuHURA Biosciences, a Phase 3 immuno-oncology company, announced a registered direct offering totaling $15.6 million through the sale of common stock and warrants across three tranches.

Summary

• TuHURA Biosciences entered into a securities purchase agreement for a registered direct offering to raise approximately $15.6 million in gross proceeds.
• The offering includes 9,462,423 shares of common stock, Series A warrants, and Series B warrants, all priced at $1.65 per share and accompanying warrants.
• The Series A and Series B warrants have an exercise price of $1.95 per share and are exercisable six months after issuance.
• The offering will close in three tranches: the first closing for $8.6 million (expected around December 10, 2025), the second for $5 million (by January 30, 2026, from K&V Investment One LLC), and the third for $2 million (by February 27, 2026, also from K&V Investment One LLC).
• Net proceeds will be used for working capital, to satisfy a $3.4 million bridge note obligation (net of $1.75 million invested by the lender), and general corporate purposes.
• H.C. Wainwright & Co. and Rodman & Renshaw LLC are acting as placement agents, receiving cash fees and Placement Agent Warrants to purchase 283,873 shares at an exercise price of $2.0625.

Sentiment

Score: 6

Explanation: The company successfully secured a significant capital raise, which is positive for its operations and debt management. However, the offering involves substantial dilution and the presence of a high-interest bridge note indicates prior financial challenges. The staggered nature of the funding also introduces some timing risk.

Positives

• Secured $15.6 million in gross proceeds, providing capital for operations and debt satisfaction.
• The offering is structured in tranches, potentially providing staggered capital infusion.
• A significant portion of the bridge note obligation ($1.75 million out of $3.4 million) is being satisfied by the lender's investment in the offering.
• The offering is registered, allowing for easier resale of securities by purchasers.

Negatives

• The offering involves the issuance of a substantial number of shares and warrants (over 9.4 million shares and an equal number of warrants), which could lead to significant dilution for existing shareholders upon exercise.
• The exercise price of the warrants ($1.95) is higher than the offering price ($1.65), but still represents a potential future dilution if exercised.
• Placement agent fees and expenses will reduce the net proceeds received by the company.
• The bridge note obligation carries a high interest rate of 3% per month, indicating previous financial strain.

Risks

• Liquidity needs to operate the business and execute strategy.
• Ability to raise capital through equity issuances, asset sales, or debt incurrence.
• Retail and credit market conditions.
• Higher cost of capital and borrowing costs.
• Impairments.
• Changes in general economic conditions.
• Other factors under 'Risk Factors' set forth in the company's Annual Report on Form 10-K, as supplemented by quarterly reports on Form 10-Q and current reports on Form 8-K.

Future Outlook

The company expects to use the net proceeds from the offering primarily for working capital, to satisfy its $3.4 million bridge note obligation to the Matthew Nachtrab Revocable Trust (net of $1.75 million invested by such lender into the Offering), and for general corporate purposes. The timing of the second and third closings is set for no later than January 30, 2026, and February 27, 2026, respectively.

Management Comments

• TuHURA Biosciences, Inc. (NASDAQ:HURA), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 9,462,423 shares of its common stock, Series A warrants to purchase up to an aggregate of 9,462,423 shares of its common stock and Series B warrants to purchase up to an aggregate of 9,462,423 shares of its common stock, at a purchase price of $1.65 per share and accompanying warrants in a registered direct offering.

Industry Context

TuHURA Biosciences is described as a 'Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy.' This offering provides capital for a company in a high-capital-intensive industry, particularly for a company with a Phase 3 clinical trial (IFx-2.0 for Merkel Cell Carcinoma) and other pipeline candidates (TBS-2025 for AML, Delta Opioid Receptor technology). The capital raise is crucial for continued R&D and operational needs in the competitive biotechnology and pharmaceutical sector.

Comparison to Industry Standards

• The offering price of $1.65 per share and warrant, with a warrant exercise price of $1.95, is a common structure for direct offerings in the biotech sector, often used to raise capital quickly.
• The placement agent fees (7.0% for the first closing, 2.0% for subsequent closings, plus warrants and expenses) are within the typical range for such offerings, reflecting the costs associated with securing institutional investment in a specialized sector like immuno-oncology.
• The use of proceeds for working capital and debt satisfaction (specifically a high-interest bridge note) is standard for development-stage biotech companies that often rely on external financing to fund their extensive R&D pipelines and operational burn rates.
• The lock-up period for directors and officers (30 days) is a common practice to signal confidence and prevent immediate selling pressure post-offering, though some offerings might have longer lock-up periods.

Related Party Transactions

• K&V Investment One LLC is a Purchaser in the Offering and has a side letter agreement for staggered funding.
• The Matthew Nachtrab Revocable Trust, holding a $3.4 million bridge note obligation, is investing $1.75 million into the offering.

Stakeholder Impact

• Shareholders: Will experience significant dilution from the issuance of new shares and potential future dilution from the exercise of warrants.
• Creditors: The satisfaction of the $3.4 million bridge note obligation will reduce the company's debt, which is positive for creditors.
• Employees/Management: The capital raise provides necessary funding for continued operations, potentially stabilizing employment and R&D efforts.
• Placement Agents: H.C. Wainwright & Co. and Rodman & Renshaw LLC will receive substantial fees and warrants for their services.

Next Steps

• First Closing of the offering on or about December 10, 2025.
• Second Closing of the offering by no later than January 30, 2026.
• Third Closing of the offering by no later than February 27, 2026.
• Company to use net proceeds for working capital, satisfaction of bridge note obligation, and general corporate purposes.
• Company to maintain listing of Common Stock and apply to list all Shares and Warrant Shares on its Trading Market.
• Company to file a Current Report on Form 8-K with the Commission.

Key Dates

Recommendation

While the capital raise addresses immediate funding needs and reduces a high-interest debt, the significant dilution from the offering and warrants, coupled with the company's ongoing need for capital in a high-risk industry (Phase 3 immuno-oncology), suggests a 'hold' position. Investors should monitor the company's progress in clinical trials and its ability to manage future financing needs without excessive dilution. The staggered nature of the funding also introduces some uncertainty.

Keywords

TuHURA Biosciences, HURA, Registered Direct Offering, Common Stock, Warrants, Capital Raise, Immuno-oncology, Biotechnology, SEC Filing, Equity Financing, Dilution, Working Capital, Bridge Note